Literature DB >> 12106935

Acetylcysteine and contrast agent-associated nephrotoxicity.

Carlo Briguori1, Fiore Manganelli, Pierfranco Scarpato, Pietro Paolo Elia, Bruno Golia, Guido Riviezzo, Stefano Lepore, Mariateresa Librera, Bruno Villari, Antonio Colombo, Bruno Ricciardelli.   

Abstract

OBJECTIVES: Prophylactic acetylcysteine along with hydration seems to be better than hydration alone in preventing the reduction in renal function induced by a contrast dye.
BACKGROUND: Contrast media can lead to acute renal failure that may occasionally require hemodialysis.
METHODS: One hundred eighty-three consecutive patients with impairment of renal function, undergoing coronary and/or peripheral angiography and/or angioplasty, were randomly assigned to receive 0.45% saline intravenously and acetylcysteine (600 mg orally twice daily; group A, n = 92) or 0.45% saline intravenously alone (group B, n = 91) before and after nonionic, low-osmolality contrast dye administration.
RESULTS: The baseline serum creatinine concentrations were similar (1.5 +/- 0.4 mg/dl in group A vs. 1.5 +/- 0.4 mg/dl in group B; p = 0.37). An increase of > or =25% in the baseline creatinine level 48 h after the procedure occurred in 6 (6.5%) of 92 patients in group A and in 10 (11%) of 91 patients in group B (p = 0.22). In the subgroup with a low (<140 ml) contrast dose, renal function deterioration occurred in 5 (8.5%) of 60 patients in group B and in 0 of 60 patients in group A (p = 0.02; odds ratio [OR] 0.44, 95% confidence interval [CI] 0.35 to 0.54). In the subgroup with a high contrast dose, no difference was found (5/31 vs. 6/32 patients, p = 0.78). By multivariate analysis, the amount of contrast agent, but not the treatment strategy, was a predictor of the occurrence of contrast dye-associated nephrotoxicity (OR 2.58, 95% CI 1.1 to 4.9; p = 0.035).
CONCLUSIONS: In patients with reduced renal function undergoing angiography and/or angioplasty, the amount of contrast agent, but not the administration of prophylactic acetylcysteine, was a predictor of renal function deterioration. Prophylactic acetylcysteine might provide better protection than hydration alone, only when a small volume of contrast agent is used.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106935     DOI: 10.1016/s0735-1097(02)01958-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  42 in total

Review 1.  Contrast nephropathy.

Authors:  Shereif H Rezkalla
Journal:  Clin Med Res       Date:  2003-10

Review 2.  How to protect from contrast media-induced nephropathy?

Authors:  B Scheller
Journal:  Clin Res Cardiol       Date:  2007-03       Impact factor: 5.460

3.  Joint quality improvement guidelines for pediatric arterial access and arteriography: from the Societies of Interventional Radiology and Pediatric Radiology.

Authors:  Manraj K S Heran; Francis Marshalleck; Michael Temple; Clement J Grassi; Bairbre Connolly; Richard B Towbin; Kevin M Baskin; Josee Dubois; Mark J Hogan; Sanjoy Kundu; Donald L Miller; Derek J Roebuck; Steven C Rose; David Sacks; Manrita Sidhu; Michael J Wallace; Darryl A Zuckerman; John F Cardella
Journal:  Pediatr Radiol       Date:  2010-02

4.  Contrast-induced nephropathy: what we know, what we think we know, and what we don't know.

Authors:  Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

5.  Are we still wondering or wandering in the dark?

Authors:  Davide Cattano
Journal:  Intern Emerg Med       Date:  2011-03-17       Impact factor: 3.397

6.  Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.

Authors:  Alper O Onbasili; Yavuz Yeniceriglu; Pinar Agaoglu; Aslihan Karul; Tarkan Tekten; Harun Akar; Guzel Discigil
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

Review 7.  Prevention of Contrast and Radiation Injury During Coronary Angiography and Percutaneous Coronary Intervention.

Authors:  Arash Ehteshami Afshar; Puja B Parikh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-22

8.  N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.

Authors:  Manouchehr Amini; Mojtaba Salarifar; Alireza Amirbaigloo; Farzad Masoudkabir; Fatemeh Esfahani
Journal:  Trials       Date:  2009-06-29       Impact factor: 2.279

Review 9.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

10.  Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy.

Authors: 
Journal:  Trials       Date:  2009-06-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.